SI-BONE, Inc. (SIBN)

SI-BONE is growing quickly (FY2025 revenue $200.93M, +20% YoY; ~22.18% 5-year revenue CAGR) and maintains very high gross margins (~79–80%), but it is still unprofitable (TTM net margin -8.10%, EBITDA margin -2.90%) with negative free cash flow (TTM FCF yield -0.73%). Liquidity is strong (TTM current ratio ~9.99; SEC filings indicate ~$145–148M cash and marketable securities) and there is no disclosed going-concern warning. A key uncertainty is regulatory/legal: the Q1 2026 10-Q discloses an ongoing DOJ investigation (CID) related to healthcare professional payments. Valuation is best viewed on sales (EV/Sales ~3.55x) given negative earnings; both analyst targets and DCF-style estimates imply upside, but execution and the DOJ outcome are central to the thesis.

The only actionable catalyst is the Q2-2026 earnings print (2026-08-03, announced, neutral-direction binary) 28 days forward; the 14-day scoring window yielded zero scorable on-topic coverage and the baseline's on-topic scored sample is sparse, so the sentiment delta is indeterminate. Red-Flag Screen clean with no caps applied, but with no market-rewarded bullish element in the actionable window the setup is weak/forming rather than mixed.

technicalScore 3 (mixed): bullish elements — price above SMA50 (18.12) and SMA200 (16.39), close at daily VWAP (18.49), Williams %R −85.71 short-term oversold, ~$9.9M 20-day dollar volume well above the $5M liquidity floor, and ATR14 at 3.78% of price (tradable range). Bearish/neutral elements — price below SMA20 (19.14), EMA9 (18.96) and EMA21 (18.90), RSI14 46.86 and falling, MACD histogram negative and contracting, and a very strong ADX14 (61.43) aligned with the recent down-leg from 20.30. Net: a mixed pullback read with no confirmed reversal trigger; the chart quality is a 3, independent of the qualitative gate that suppresses the trade.